Bioverativ Inc Stock

Stocks

18-04-27	Sanofi : sees new acquisitions and drugs reviving growth	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-28	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
18-02-15	Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	RE
18-02-07	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
18-01-29	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
18-01-22	Stocks hit record as senators reach deal to end shutdown	RE
18-01-22	Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	RE
18-01-22	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
18-01-22	Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

18-03-06	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
18-02-14	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
18-02-13	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
18-01-24	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
18-01-24	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR

18-03-28	Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
18-03-08	Sanofi finalise l'acquisition de Bioverativ
18-03-08	Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
18-02-23	Sanofi : franchit une étape dans son offre sur Bioverativ
18-02-07	Sanofi: Amélioration attendue en 2018 plus lente que prévu

Manager	Title	Age	Since
Brian Foard PSD	President	-	-
Timothy Harris PRN	Corporate Officer/Principal	76	2017-01-31
Joann Nestor SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Philippe Sauvage BRD	Director/Board Member	49	2018-03-07
Brian Foard BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOVERATIV INC	-.--%	+0.30%	-	-	0
ARGENX SE	-0.68%	-4.74%	+63.04%	+125.09%	56.98B
WUXI APPTEC CO., LTD.	+4.91%	-0.19%	+73.70%	+92.14%	53.58B
INSMED INCORPORATED	+1.48%	+5.97%	+22.59%	+495.47%	25.63B
BIONTECH SE	-0.59%	-4.68%	-16.82%	-12.99%	23.51B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.43B
GENMAB A/S	-1.61%	+1.93%	+36.57%	-25.46%	18.12B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+203.03%	+348.11%	16.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	14.13B
EXELIXIS, INC.	+1.76%	+2.24%	+29.57%	+195.70%	14.35B
Average	+0.96%	+0.86%	+57.02%	+152.24%	26.91B
Weighted average by Cap.	+1.25%	-0.31%	+57.14%	+142.65%

Employees

Sector